Shanghai Haohai Biological Technology Co.,Ltd. has announced that its controlled subsidiary, Henan Saimeishi Biotechnology Co., Ltd., has recently obtained the Medical Device Registration Certificate from the National Medical Products Administration for a trifocal intraocular lens product.

This product is indicated for the correction of vision in adult cataract patients with aphakia, aiming to improve near, intermediate, and distance vision and reduce dependence on glasses. The intraocular lens is designed for implantation into the capsular bag.

This lens represents another multifocal intraocular lens product approved for the company this year, accelerating and enhancing its strategic layout within the high-end multifocal lens segment and injecting fresh momentum into the development of its ophthalmology business.

This achievement successfully validates the feasibility of the company's original technological breakthroughs under its medical-engineering collaboration model, marking the company's established capability for original design and systematic development centered around clinical needs, which supports the company's sustained high-quality development in the ophthalmology field.